ESMO 2017 : Pembrolizumab in head and neck cancer: a clinically meaningful difference and a lower toxicity in advanced forms

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Immunotherapy with the checkpoint inhibitor pembrolizumab may be an alternative to standard treatments (because of lower toxicity) for patients with recurrent or metastatic head and neck cancer after chemotherapy, according to results of the Keynote-040 trial.
  • The treatment effect...